David James Owen

David James Owen is a notable inventor based in Kew, Australia. He has made significant contributions to the field of therapeutic dendrimers, holding a total of eight patents. His work focuses on developing advanced pharmaceutical compositions that have the potential to treat various disorders, including cancers.

Latest Patents

Among his latest patents is a therapeutic dendrimer that comprises a core unit and five generations of building units made from lysine residues or their analogues. The dendrimer features first terminal groups that include a cabazitazel residue covalently attached to a diglycolyl linker group, along with second terminal groups that consist of a PEG group. These dendrimers are not only innovative in their structure but also in their application, as they are designed for use in pharmaceutical compositions aimed at treating disorders such as cancers. Additionally, the patents detail processes for making the dendrimers and their intermediates.

Career Highlights

David has worked with several prominent organizations throughout his career. Notably, he has been associated with Starpharma Pty Limited and the Baker Heart and Diabetes Institute Holdings Limited. His work in these institutions has allowed him to further his research and development in the field of dendrimer technology.

Collaborations

Throughout his career, David has collaborated with esteemed colleagues, including Brian Devlin Kelly and Peter Karellas. These collaborations have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

David James Owen's innovative work in the field of therapeutic dendrimers showcases his dedication to advancing medical science. His contributions have the potential to significantly impact the treatment of various disorders, particularly cancers.

This text is generated by artificial intelligence and may not be accurate.